News

Sarepta Therapeutics traded lower on Monday, extending a slide as the company took the unusual step of refusing a Food and ...
Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...
Sarepta Therapeutics announced it is laying off nearly 500 employees this week, including 80 at its Easton location.
Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.
The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...
Sarepta says it will continue to ship Elevidys despite FDA requests that it stop shipments of the Duchenne muscular dystrophy gene therapy, while Verizon tops earnings expectation and raises 2025 ...
Key Takeaways Sarepta Therapeutics shares were down roughly 17% late Friday morning.The tumble followed a report that a third ...
Retail chatter spiked last week as investors piled into three healthcare stocks: GlucoTrack, Sarepta Therapeutics, and TNF Pharmaceuticals, which recorded the highest increases in message volume among ...